LAKESHORE BIOPHARMA CO LTD (LSB) Stock Overview
USA - NASDAQ:LSB - KYG9845F2080 - Common Stock
LSB Key Statistics, Chart & Performance
The current stock price of LSB is 0.627 USD. In the past month the price decreased by -25%. In the past year, price decreased by -18.57%.
LSB Latest News, Press Relases and Analysis
LSB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.85 | 408.76B | ||
| AMGN | AMGEN INC | 13.81 | 162.12B | ||
| GILD | GILEAD SCIENCES INC | 16.03 | 153.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.16 | 109.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.69 | 61.40B | ||
| ARGX | ARGENX SE - ADR | 90.64 | 51.39B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.1 | 34.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.70B | ||
| NTRA | NATERA INC | N/A | 25.65B | ||
| BIIB | BIOGEN INC | 9.13 | 21.44B |
Related stock screener links
About LSB
Company Profile
LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 573 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Company Info
LAKESHORE BIOPHARMA CO LTD
Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District
Beijing BEIJING CN
Employees: 573
Phone: 17327133678
LAKESHORE BIOPHARMA CO LTD / LSB FAQ
What is the stock price of LAKESHORE BIOPHARMA CO LTD today?
The current stock price of LSB is 0.627 USD. The price decreased by -20.68% in the last trading session.
What is the ticker symbol for LAKESHORE BIOPHARMA CO LTD stock?
The exchange symbol of LAKESHORE BIOPHARMA CO LTD is LSB and it is listed on the Nasdaq exchange.
On which exchange is LSB stock listed?
LSB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LAKESHORE BIOPHARMA CO LTD stock?
5 analysts have analysed LSB and the average price target is 31.62 USD. This implies a price increase of 4943.06% is expected in the next year compared to the current price of 0.627. Check the LAKESHORE BIOPHARMA CO LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LAKESHORE BIOPHARMA CO LTD worth?
LAKESHORE BIOPHARMA CO LTD (LSB) has a market capitalization of 25.84M USD. This makes LSB a Nano Cap stock.
How many employees does LAKESHORE BIOPHARMA CO LTD have?
LAKESHORE BIOPHARMA CO LTD (LSB) currently has 573 employees.
What are the support and resistance levels for LAKESHORE BIOPHARMA CO LTD (LSB) stock?
LAKESHORE BIOPHARMA CO LTD (LSB) has a resistance level at 0.78. Check the full technical report for a detailed analysis of LSB support and resistance levels.
Is LAKESHORE BIOPHARMA CO LTD (LSB) expected to grow?
The Revenue of LAKESHORE BIOPHARMA CO LTD (LSB) is expected to grow by 75.61% in the next year. Check the estimates tab for more information on the LSB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LAKESHORE BIOPHARMA CO LTD (LSB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LSB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LSB, evaluating the profitability, health, valuation and growth aspects
- LAKESHORE BIOPHARMA CO LTD (LSB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LAKESHORE BIOPHARMA CO LTD (LSB) Sales and EPS estimates to see what analysts future expectations are.
- LAKESHORE BIOPHARMA CO LTD (LSB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LAKESHORE BIOPHARMA CO LTD (LSB) Insider and Institutional Ownership to learn about the owners and their transactions.
- LAKESHORE BIOPHARMA CO LTD (LSB) Stock Chart to make your own analysis
- LAKESHORE BIOPHARMA CO LTD (LSB) Latest news and press-releases to stay up to date.
Does LAKESHORE BIOPHARMA CO LTD (LSB) stock pay dividends?
LSB does not pay a dividend.
When does LAKESHORE BIOPHARMA CO LTD (LSB) report earnings?
LAKESHORE BIOPHARMA CO LTD (LSB) will report earnings on 2025-12-15.
What is the Price/Earnings (PE) ratio of LAKESHORE BIOPHARMA CO LTD (LSB)?
LAKESHORE BIOPHARMA CO LTD (LSB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
What is the Short Interest ratio of LAKESHORE BIOPHARMA CO LTD (LSB) stock?
The outstanding short interest for LAKESHORE BIOPHARMA CO LTD (LSB) is 0.35% of its float. Check the ownership tab for more information on the LSB short interest.
LSB Technical Analysis
LSB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LSB. LSB has a bad profitability rating. Also its financial health evaluation is rather negative.
LSB Financial Highlights
Over the last trailing twelve months LSB reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 87.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.31% | ||
| ROE | -20.01% | ||
| Debt/Equity | 0.05 |
LSB Forecast & Estimates
5 analysts have analysed LSB and the average price target is 31.62 USD. This implies a price increase of 4943.06% is expected in the next year compared to the current price of 0.627.
For the next year, analysts expect an EPS growth of 105.67% and a revenue growth 75.61% for LSB